Provisional Conference Program
Thursday 24th May 2007
SESSION 5:
DNA VACCINES CLINICAL TRIALS
Moderator: Britta Wahren (Karolinska Institute, Stockholm, Sweden)
08.30-09.00
‘Development of therapeutic HPV DNA vaccines’
T.C. Wu (The Johns Hopkins University, Baltimore, Maryland, USA)
09.00-09.30
‘Development and immunogenicity of RNA- and Codon-optimized HIV candidate vaccines in phase-I clinical trials’
Ralf Wagner et al. (GENEART GmbH, Regensburg, Germany)
09.30-09.50
‘DNA vaccines for autoimmune diseases: results from a phase I/II clinical trial of a plasmid (BHT-3009) for multiple sclerosis, and interim results of a phase I/II clinical trial of a DNA plasmid (BHT-3021) for type 1 diabetes’
Hideki Garren (Bayhill Therapeutics Inc., Palo Alto, California, USA)
09.50-10.10
‘Increased immunogenicity and efficacy of optimised HBV DNA vaccine against chronic hepatitis B in transgenic mice model and clinical trial’
Sehwan Yang et al. (Pohang University of Science and Technology, Pohang, Republic of Korea)
10.10-10.20
Coffee Break & Poster Session B & Exhibits
SESSION 6:
DNA VACCINES MANUFACTURING
Moderator: Shan Lu (University of Massachusetts, USA)
10.20-10.40
‘ORT-VAC: Live bacterial vectors for vaccine delivery’
Rocky H. Cranenburgh et al. (Cobra Biomanufacturing Plc., Keele, UK)
10.40-11.00
‘Building and validating a commercial scale plasmid DNA manufacturing facility’
Rick Hancock (Althea Technologies Inc., USA)
11.00-11.20
‘Minicircle DNA production for DNA vaccines’
Martin Schleef (PlasmidFactory GmbH, Germany)
11.20-11.40
‘A unique approach to potency assay for DNA vaccines’
Keith D. Hall (Vical Inc., San Diego, California, USA)
11.40-12.00
‘Antibiotic-free plasmid selection for next generation DNA vaccines’
Hans Huber (Boehringer-Ingelheim Austria GmbH, Vienna, Austria)
12.00-12.20
‘Increasing fermentation yield and elimination of alkaline lysis and chromatography steps for plasmid DNA production’
Aaron Carnes, Jim Williams, Jeremy Luke, Sarah Langtry and Clague Hodgson (Nature Technology Corporation, Lincoln, Nebraska, USA)
12.20-12.40
‘Development of a cost effective method to produce multivalent plasmid products’
Gary Gates, Hugo Gonzalez, Henry Hebel and C. Satishchandran (Nucleonics Inc., Horsham, Pennsylvania, USA/ADViSYS Inc., The Woodland, Texas, USA)
12.40-14.00
Lunch Break & Poster Session B & Exhibits
SESSION 7:
HIV DEVELOPMENTS
Moderator: C. Jo White (VGX Pharma, USA)
14.00-14.30
‘Concepts and results in humans on designing an effective HIV DNA vaccine’
Britta Wahren (Karolinska Institute, Stockholm, Sweden)
14.30-15.00
‘Understanding correlates of protective HIV-specific cell mediated immunity’
Michael R. Betts (University of Pennsylvania, Philadelphia, USA)
15.00-15.20
‘Update on the immunogenicity of a polyvalent DNA prime-protein boost HIV-1 vaccine formulation DP6-001 in healthy volunteers’
Shan Lu, J. Kennedy, S. Wang, K. West, P. Goepfert, F.A. Ennis, R. Pal and P. Markham (University of Massachusetts, Worcester, MA, USA)
15.20-15.40
‘Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell mediated immune responses’
M. Egan, S. Megati et al. (Wyeth Vaccines Research, Pearl River, New York, USA)
15.40-16.00
‘Intranasal immunization with a multigene HIV-1 vaccine in combination with the Eurocine™ N3 adjuvant is safe and induces systemic and mucosal immune responses’
Jorma Hinkula, Ulf Schröder et al. (Linkoping University, Sweden)
16.00-16.30
Tea Break & Poster Session B & Exhibits
SESSION 8:
CANCER I
Moderator: Freda Stevenson (University of Southampton, UK)
16.30-17.00
‘Of mice and men, and dogs: Approval of a Xenogeneic DNA vaccine for dogs with malignant melonoma’
Philip J. Bergman (MSKCC, New York, USA)
17.00-17.20
‘Clinical-grade anti-idiotype plasmid DNA vaccines for B-cell lymphomas: From bench (to regulatory authorities) to bedside’
Daniele Focosi, Mario Petrini, Oscar Roberto Burrone and Maria Luisa Nolli (Universitaria Santa Chiara, Pisa, Italy)
17.20-17.40
‘DNA fusion vaccine delivery by electroporation – a well tolerated strategy for immunotherapy in prostate cancer’
Christian Ottensmeier (Southampton Universities Hospitals Trust, Southampton, UK) and Iacob Mathiesen (INOVIO, San Diego, California, USA)
Reception & Poster Session B
Sponsored by VGX Pharma
